ARDX
Ardelyx, Inc.
stockNASDAQ
ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 3.20 | 2026-10-22 | -3.43% | 2.286 |
| 1M | 3.39 | 2026-09-29 | -8.85% | 0.320 |
| 3M | 5.00 | 2026-07-29 | -38.20% | 0.395 |
| 6M | 6.01 | 2026-04-29 | -48.58% | 0.195 |
| 1Y | 4.96 | 2025-10-29 | -37.70% | 0.818 |
| 2Y | 6.01 | 2024-10-29 | -48.58% | — |
| 5Y | 1.21 | 2021-10-29 | +155.38% | 0.580 |
Ardelyx, Inc. (NASDAQ:ARDX) stock price today is $3.09, and today's volume is 1,106,203. ARDX is down 0.319% today. The 30 day average volume is 4.38M. ARDX market cap is $797.83M with 258.19M shares outstanding.